Latest Headlines

1. Mangoceuticals Selects TRYBE Labs As Its Nationwide Blood Collection And Testing Services Provider 11/29/2023

   Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product branded ‘GROW’ and erectile dysfunction (ED) drug branded “Mango,” today announced that it has selected TRYBE Labs to provide its customers with a minimally invasive FDA approved at-home blood collection device and testing services as the Company seeks to further expand its product lines requiring blood tests and results reviewed by physicians.

2. Atalan Adds Tricore To Its Technology-Enabled Clinical Partnership, Providing Greater Access To The Best In Laboratory Medicine 11/29/2023

   Atalan, the technology-enabled clinical partnership providing doctors and medical centers unprecedented access to a vetted network of the nation's foremost clinical laboratories, announced today the addition of TriCore to its network.

3. Xact Laboratories Announces Strategic Partnership With A National Switch To Provide Integrated PGx Results At The Point Of Prescription Fulfillment 11/29/2023

   Xact Laboratories LLC (Xact), a biotechnology company focusing on integrated pharmacogenomic (PGx) test results at the point of care, is excited to announce a groundbreaking partnership with a national prescription claims clearinghouse (commonly known as a "Switch"), to automate the integration of cutting-edge pharmacogenomic testing results to aid providers in optimizing prescription medical therapy for members from participating health plans.

4. ARUP Laboratories Urges FDA To Withdraw Proposed Rule Regulating Laboratory-Developed Tests 11/29/2023

   ARUP Laboratories today released the company's public comment on the FDA's proposed rule to regulate laboratory-developed tests (LDTs) as medical devices, urging the agency to withdraw the rule.

5. Personalis And Tempus Enter Into A Strategic Collaboration To Advance Cancer Testing 11/28/2023

   Personalis, Inc., a leader in advanced genomics for precision oncology, and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal Dx, Personalis’ whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer.

6. New Advanced Diagnostic Tests Lab To Perform, Interpret Clinical-Grade Molecular Testing Of Biomarkers 11/28/2023

   The Yale Advanced Diagnostic Tests Laboratory (ADT) in the Department of Pathology is a new unit of Yale Pathology Labs (YPL).

7. Formapath Announces Advancement In Cancer Pathology With The Launch Of AdiPress 11/28/2023
8. Lilly Announces Plans To Open Its First-Ever Gateway Labs Site In San Diego 11/28/2023

   Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024.

9. Inflammatix Receives Breakthrough Device Designation From FDA For TriVerity™ Acute Infection And Sepsis Test System 11/28/2023

   Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company's lead product, the TriVerity™ Acute Infection and Sepsis Test System.

10. Quest Diagnostics And Scipher Medicine Collaborate To Scale Precision Medicine Access For Patients With Rheumatoid Arthritis 11/28/2023

    Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).